You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

16 Results
Guidelines and Advice
Status: Archived
ID: SCT 4
Dec 2012
Guidelines and Advice
Guidelines and Advice
Status: In-Review
ID: SCT 1
Mar 2012
Guidelines and Advice
Jul 2012
Guidelines and Advice
Guidelines and Advice
Drug
Other Name(s): Sylvant®
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Mar 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
Apr 2025
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Sacituzumab Govitecan - Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer
New Drug Funding Program
    Sacituzumab Govitecan - HR-positive HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Jul 2025
Drug
Other Name(s): Trodelvy®
Jul 2025

Pages